Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer in China.
Xin ZhangHuixian ZhangLan-Fang LiLei FengQiao LiuPublished in: Risk management and healthcare policy (2023)
From the perspective of the Chinese health care system, first-line Pembro+Chemo emerges as a dominant treatment option over Placebo+Chemo for the treatment of metastatic squamous NSCLC.